SpyGlass Pharma names Mike Pinder as VP of marketing
Get Alerts SGP Hot Sheet
Join SI Premium – FREE
SpyGlass Pharma Inc. (NASDAQ: SGP) appointed Mike Pinder as vice president of marketing, the company announced. Pinder brings more than 20 years of commercial launch experience in ophthalmology.
At SpyGlass Pharma, Pinder will build and lead the marketing function as the company progresses its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials toward potential commercialization upon FDA approval.
Pinder was most recently head of IZERVAY marketing at Astellas Pharma. He previously led patient marketing in the Novartis ophthalmology retina franchise and held hospital marketing positions at Johnson & Johnson. He holds a Bachelor of Arts degree in communications from the University of Massachusetts Amherst.
"Mike's deep experience in building successful ophthalmology brands across buy-and-bill specialty pharma and medical device products will augment our plans for a successful BIM-IOL launch," said Patrick Mooney, chief executive officer of SpyGlass Pharma.
SpyGlass Pharma is currently enrolling participants in two Phase 3 trials for its BIM-IOL System. The company focuses on developing sustained drug delivery solutions for chronic eye conditions.
The information is based on a company press release.
You May Also Be Interested In
- Marvell names Dan Durn as CFO effective June 15, 2026
- Profusa submits response to European regulator for Lumee device review
- Shell pauses $3 billion share buyback program due to ARC deal
Create E-mail Alert Related Categories
Management ChangesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share